ENXTPA:IPNPharmaceuticals
Ipsen (ENXTPA:IPN) Valuation Check As Strong 2025 Results And Upbeat 2026 Outlook Lift Investor Optimism
Ipsen (ENXTPA:IPN) is back in focus after reporting 2025 results alongside fresh 2026 guidance, combining double digit sales and profit growth with expectations for further expansion across its portfolio and pipeline.
See our latest analysis for Ipsen.
The recent 4.81% 1 day share price return, together with a 33.25% year to date share price return and 40.87% 1 year total shareholder return, points to momentum building as investors react to Ipsen's 2025 results, 2026 guidance and recent...